Tissue | Expression Dynamics | Abbreviation |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/TFPI_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/TFPI_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/TFPI_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/TFPI_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/TFPI_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/TFPI_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004206016 | Endometrium | AEH | wound healing | 91/2100 | 422/18723 | 4.85e-10 | 4.61e-08 | 91 |
GO:004854516 | Endometrium | AEH | response to steroid hormone | 76/2100 | 339/18723 | 2.15e-09 | 1.77e-07 | 76 |
GO:005254716 | Endometrium | AEH | regulation of peptidase activity | 85/2100 | 461/18723 | 2.47e-06 | 7.11e-05 | 85 |
GO:00323557 | Endometrium | AEH | response to estradiol | 34/2100 | 141/18723 | 1.13e-05 | 2.53e-04 | 34 |
GO:007138310 | Endometrium | AEH | cellular response to steroid hormone stimulus | 44/2100 | 204/18723 | 1.41e-05 | 3.01e-04 | 44 |
GO:005254816 | Endometrium | AEH | regulation of endopeptidase activity | 76/2100 | 432/18723 | 4.42e-05 | 7.43e-04 | 76 |
GO:000223710 | Endometrium | AEH | response to molecule of bacterial origin | 65/2100 | 363/18723 | 9.00e-05 | 1.30e-03 | 65 |
GO:003249610 | Endometrium | AEH | response to lipopolysaccharide | 62/2100 | 343/18723 | 9.82e-05 | 1.41e-03 | 62 |
GO:004586116 | Endometrium | AEH | negative regulation of proteolysis | 63/2100 | 351/18723 | 1.07e-04 | 1.53e-03 | 63 |
GO:00075967 | Endometrium | AEH | blood coagulation | 43/2100 | 217/18723 | 1.42e-04 | 1.89e-03 | 43 |
GO:00075997 | Endometrium | AEH | hemostasis | 43/2100 | 222/18723 | 2.39e-04 | 2.86e-03 | 43 |
GO:00508177 | Endometrium | AEH | coagulation | 43/2100 | 222/18723 | 2.39e-04 | 2.86e-03 | 43 |
GO:005134610 | Endometrium | AEH | negative regulation of hydrolase activity | 65/2100 | 379/18723 | 3.18e-04 | 3.57e-03 | 65 |
GO:005087815 | Endometrium | AEH | regulation of body fluid levels | 64/2100 | 379/18723 | 5.40e-04 | 5.44e-03 | 64 |
GO:190303410 | Endometrium | AEH | regulation of response to wounding | 32/2100 | 167/18723 | 1.69e-03 | 1.36e-02 | 32 |
GO:00610419 | Endometrium | AEH | regulation of wound healing | 27/2100 | 134/18723 | 1.77e-03 | 1.41e-02 | 27 |
GO:00712229 | Endometrium | AEH | cellular response to lipopolysaccharide | 37/2100 | 209/18723 | 3.30e-03 | 2.31e-02 | 37 |
GO:00712169 | Endometrium | AEH | cellular response to biotic stimulus | 42/2100 | 246/18723 | 3.65e-03 | 2.50e-02 | 42 |
GO:001046610 | Endometrium | AEH | negative regulation of peptidase activity | 43/2100 | 262/18723 | 6.78e-03 | 3.95e-02 | 43 |
GO:00712199 | Endometrium | AEH | cellular response to molecule of bacterial origin | 37/2100 | 221/18723 | 8.34e-03 | 4.56e-02 | 37 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TFPI | SNV | Missense_Mutation | novel | c.516G>T | p.Lys172Asn | p.K172N | P10646 | protein_coding | deleterious(0.04) | benign(0.326) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
TFPI | SNV | Missense_Mutation | | c.821G>T | p.Arg274Ile | p.R274I | P10646 | protein_coding | deleterious(0) | possibly_damaging(0.641) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
TFPI | SNV | Missense_Mutation | novel | c.203A>C | p.Lys68Thr | p.K68T | P10646 | protein_coding | tolerated(0.57) | benign(0.062) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
TFPI | SNV | Missense_Mutation | rs765177048 | c.680N>A | p.Arg227His | p.R227H | P10646 | protein_coding | tolerated(0.06) | benign(0.077) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TFPI | SNV | Missense_Mutation | | c.31N>A | p.Leu11Ile | p.L11I | P10646 | protein_coding | tolerated(0.08) | benign(0.039) | TCGA-D1-A0ZN-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
TFPI | SNV | Missense_Mutation | | c.656N>T | p.Thr219Ile | p.T219I | P10646 | protein_coding | deleterious(0.03) | benign(0.11) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TFPI | SNV | Missense_Mutation | novel | c.136C>T | p.Pro46Ser | p.P46S | P10646 | protein_coding | deleterious(0.05) | benign(0.043) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
TFPI | SNV | Missense_Mutation | novel | c.739T>C | p.Tyr247His | p.Y247H | P10646 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TFPI | SNV | Missense_Mutation | | c.206N>A | p.Arg69Lys | p.R69K | P10646 | protein_coding | tolerated(0.11) | benign(0.057) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TFPI | SNV | Missense_Mutation | | c.238N>A | p.Glu80Lys | p.E80K | P10646 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EO-A3AY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7035 | TFPI | CELL SURFACE, DRUGGABLE GENOME, PROTEASE INHIBITOR | | PI-88 | MUPARFOSTAT | 11292191 |
7035 | TFPI | CELL SURFACE, DRUGGABLE GENOME, PROTEASE INHIBITOR | | CHONDROITIN SULFATE | | 10959709 |
7035 | TFPI | CELL SURFACE, DRUGGABLE GENOME, PROTEASE INHIBITOR | | AZITHROMYCIN | AZITHROMYCIN | 16113783 |
7035 | TFPI | CELL SURFACE, DRUGGABLE GENOME, PROTEASE INHIBITOR | | HEPARIN | HEPARIN | 11150580 |
7035 | TFPI | CELL SURFACE, DRUGGABLE GENOME, PROTEASE INHIBITOR | | NN-7415 | | |
7035 | TFPI | CELL SURFACE, DRUGGABLE GENOME, PROTEASE INHIBITOR | | LOVASTATIN | LOVASTATIN | 7600119 |
7035 | TFPI | CELL SURFACE, DRUGGABLE GENOME, PROTEASE INHIBITOR | | CREMOPHOR | | 9352228 |
7035 | TFPI | CELL SURFACE, DRUGGABLE GENOME, PROTEASE INHIBITOR | | ATORVASTATIN | ATORVASTATIN | 15792677 |
7035 | TFPI | CELL SURFACE, DRUGGABLE GENOME, PROTEASE INHIBITOR | | FULVESTRANT | FULVESTRANT | 17029634 |
7035 | TFPI | CELL SURFACE, DRUGGABLE GENOME, PROTEASE INHIBITOR | | CHONDROITIN | | 7974391 |